Selected Innovative Medicines in Development as of October 14, 2025
24
19
38
22
103
Phase 1
Phase 2
Phase 3
Registration
Total

Oncology (1 of 3)
AKEEGA (niraparib/abiraterone)
DARZALEX (daratumumab)
DARZALEX (daratumumab)
M1 Metastatic Castration-Sensitive Prostate Cancer 
(AMPLITUDE)
Smoldering Multiple Myeloma (AQUILA)
Frontline multiple myeloma transplant ineligible 
(CEPHEUS)
IMBRUVICA (ibrutinib)
IMBRUVICA (ibrutinib)
INLEXZO (gemcitabine intravesical system) 
Frontline Chronic Lymphocytic Leukemia (I + V fixed 
duration) (GLOW)
Frontline Mantle Cell Lymphoma (Triangle)
Non Muscle Invasive Bladder Cancer (SunRISe-1)
RYBREVANT (amivantamab)
RYBREVANT (amivantamab)
Bleximenib 
Frontline Non Small Cell Lung Cancer in combination with 
chemotherapy (PAPILLON)
Subcutaneous (PALOMA-3)
Newly Diagnosed AML, chemo ineligible in combination 
with Venetoclax and Azacitidine (cAMeLot-2)
CARVYKTI (Ciltacabtagene autoleucel)
CARVYKTI (Ciltacabtagene autoleucel)
ERLEADA (apalutamide)
Frontline Multiple Myeloma TNI (CARTITUDE-5)
Frontline Multiple Myeloma Transplant Eligible vs ASCT 
(CARTITUDE-6)
Localized Prostate Cancer (ATLAS)
ERLEADA (apalutamide)
INLEXZO (gemcitabine intravesical system) 
INLEXZO (gemcitabine intravesical system) 
High Risk Prostate Cancer (PROTEUS)
Non Muscle Invasive Bladder Cancer BCG-naïve High Risk 
(SunRISe-3)
High Risk Non Muscle Invasive Bladder Cancer BGC 
Experienced (SunRISe-5)
JNJ-1900 (NBTXR3) 
pasritamig 
RYBREVANT (amivantamab)
Head and Neck Cancer
Prostate Cancer
Colorectal Cancer (ORIGAMI-2)
RYBREVANT (amivantamab)
TALVEY + TECVAYLI 
TALVEY (talquetamab)
Colorectal Cancer 2L (ORIGAMI-3)
Relapsed Refractory Multiple Myeloma CD38 exposed 
(MonumenTAL-6)
Relapsed Refractory Multiple Myeloma A-CD38 Naïve 
(MonumenTAL-3)
TALVEY (talquetamab)
TALVEY (talquetamab)
TAR-210 (RIS/erdafitinib)
Relapsed Refractory Multiple Myeloma CD38 exposed 
(MonumenTAL-6)
TIE NDMM in combination with DR (MajesTEC-7)
Intravesical Delivery System for Localized Bladder 
Cancer (MoonRISe-1)

Oncology (2 of 3)
TECVAYLI (teclistamab)
TECVAYLI (teclistamab)
TECVAYLI (teclistamab)
Multiple Myeloma 1-3PLs (MajesTEC-3)
TE NDMM maintenance (MajesTEC-4)
TIE NDMM in combination with DR (MajesTEC-7)
TECVAYLI (teclistamab)
bleximenib 
JNJ-0683 (ARX788)
Relapsed Refractory Multiple Myeloma CD38 exposed 
(MajesTEC-9)
Relapsed Refractory Acute Myeloid Leukemia (ALE1001)
Breast Cancer
JNJ-1900 (NBTXR3) 
TALVEY + TECVAYLI 
JNJ-0387 
Lung Cancer
Relapsed Refractory Multiple Myeloma (RedirecTT-1)
Solid Tumors
JNJ-0631 (ARX305)
JNJ-1493 
JNJ-2638 
Renal Cancer
Hematological Malignancies
Gastrointestinal Cancer
JNJ-2761 
JNJ-3413 
JNJ-4496 
Multiple Myeloma
Lymphoma
Hematological Malignancies
JNJ-4680 
JNJ-4681 
JNJ-4916 
Lung Cancer
Hematological Malignancies
Lung Cancer
JNJ-5322 
JNJ-6420 
JNJ-7446 
Multiple Myeloma
Prostate Cancer
Lung Cancer
JNJ-8177 (ARX517)
JNJ-8377 
JNJ-8543 
Prostate Cancer
Lymphoma
Hematological Malignancies

Oncology (3 of 3)
JNJ-9401 
JNJ-9530 
JNJ-9892 
Prostate Cancer
Hematological Malignancies
Hematological Malignancies
JNJ-9968 
Hematological Malignancies

Immunology (1 of 2)
icotrokinra 
SIMPONI (golimumab)
STELARA (ustekinumab)
Psoriasis (ICONIC)
Pediatric Ulcerative Colitis (PURSUIT 2)
Pediatric Crohn's Disease (UNITI JR)
STELARA (ustekinumab)
TREMFYA (guselkumab)
TREMFYA (guselkumab)
Pediatric Juvenile Psoriatic Arthritis
Pediatric Psoriasis (PROTOSTAR)
Psoriatic Arthritis Structural Damage (APEX)
TREMFYA (guselkumab)
TREMFYA (guselkumab)
icotrokinra 
Ulcerative Colitis Subcutaneous Induction (ASTRO)
Pediatric Juvenile Psoriatic Arthritis
Psoriatic Arthritis
nipocalimab​ 
nipocalimab​ 
nipocalimab​ 
Warm Autoimmune Hemolytic Anemia (ENERGY)
Sjogren's Disease
Hemolytic Disease of the Fetus and Newborn (AZALEA)
nipocalimab​ 
STELARA (ustekinumab)
TREMFYA (guselkumab)
Fetal and Neonatal Alloimmune Thrombocytopenia 
(FREESIA)
Pediatric Ulcerative Colitis (UNIFI JR)
Pediatric Crohn's Disease (MACARONI-23)
TREMFYA (guselkumab)
icotrokinra 
JNJ-4804 Co-antibody Therapy 
Pediatric Ulcerative Colitis (QUASAR JR)
Ulcerative Colitis
Ulcerative Colitis
JNJ-4804 Co-antibody Therapy 
JNJ-4804 Co-antibody Therapy 
JNJ-5939 
Psoriatic Arthritis
Crohn's Disease
Atopic Dermatitis
nipocalimab​ 
nipocalimab​ 
JNJ-5108 
Systemic Lupus Erythematosus
Idiopathic Inflammatory Myopathy
Immunological Diseases

Immunology (2 of 2)
JNJ-6848 
JNJ-7528 
Immunological Diseases
Atopic Dermatitis

Neuroscience
CAPLYTA (lumateperone)
IMAAVY (nipocalimab​)
IMAAVY (nipocalimab​)
Adjunctive Treatment for Major Depressive Disorder
Generalized Myasthenia Gravis (Vivacity MG3)
Generalized Myasthenia Gravis Pediatrics (VIBRANCE MG)
SPRAVATO (esketamine)
CAPLYTA (lumateperone)
CAPLYTA (lumateperone)
Treatment Resistant Depression monotherapy (TRD4005)
Bipolar Mania
Pediatric Psychiatric Indications
nipocalimab​ 
RPGR Gene Therapy 
seltorexant 
Chronic Inflammatory Demyelinating Polyneuropathy 
(ARISE)
Retinitis Pigmentosa (LUMEOS)
Adjunctive Treatment for Major Depressive Disorder with 
Insomnia Symptoms (OARS)
ITI-1284 
ITI-1284 
ITI-1284 
Generalized Anxiety Disorder
Alzheimer's Disease-Related Psychosis
Alzheimer's Disease-Related Agitation
JNJ-1887​ sCD59 
JNJ-2056 (tau active immunotherapy) *
JNJ-5120 
Geographic Atrophy
Alzheimer's Disease (RETAIN)
Major Depressive Disorder
posdinemab 
SPRAVATO (esketamine)
Alzheimer's Disease (AUTONOMY)
Major Depressive Disorder with Suicidal Ideation 
Pediatrics

Select Other Areas
CABENUVA 
UPTRAVI (selexipag)
macitentan 
HIV Adolescents
Pediatric Pulmonary Arterial Hypertension (SALTO)
Pulmonary Arterial Hypertension 75mg (UNISUS)
milvexian (Factor Xla)
milvexian (Factor Xla)
milvexian (Factor Xla)
Secondary Stroke Prevention
Acute Coronary Syndrome
Atrial Fibrillation
SIRTURO 
SIRTURO 
Leprosy
Tuberculosis Long Acting
*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these 
programs and assets and does not guarantee continued investment.  This information is as of October 14, 2025 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.  *AC Immune ACI-35.030. 
Strategic Partnerships, Collaborations, and Licensing arrangements -milvexian: Bristol Myers Squibb; AAV-RPGR: UCL Business Plc; JNJ-1887: Hemera Biosciences;  Long acting HIV injectible treatment regimen of rilpivirine and cabotegravir: ViiV Healthcare; 
REMICADE and SIMPONI/SIMPONI ARIA: Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA: MorphoSys AG; JNJ-2113: Protagonist Therapeutics; Tau Immunotherapy: AC Immune SA; 
IMBRUVICA: Pharmacyclics, LLC, an AbbVie company; ZYTIGA: BTG International;  DARZALEX and DARZALEX FASPRO: Genmab A/S; ERLEADA: Regents of California and Memorial Sload Kettering; CARVYKTI: Legend Biotech; AKEEGA: TESARO, an oncology-
focused business within GSK; lazertinib: Yuhan Corporation; Duobody Platform bispecific antibody programs: Genmab A/S; ENHANZE platform; Halozyme Therapeutics; XmAb CD28 bispecific antibodies; Xencor; iPSC-derived chimeric antigen receptor 
(CAR) NK and CAR T-cell product candidates: Fate Therapeutics; UPTRAVI and OPSUMIT: Nippon Shinyaku (co-promotion in Japan); CD20-directed autologous CAR-Ts: Cellular Biomedicine Group, Inc. (CBMG); muscarinic M1 receptor antagonist: Pipeline 
Therapeutics; NBTXR3: Nanobiotix; A2a Receptor Antagonist: AdoRx Therapeutics Limited
